• PCV24 COST EFFECTIVENESS OF THE CARDIOVASCULAR PREVENTION WITH RAMIPRIL AND/OR STATINS IN HIGH RISK POPULATION IN ITALY

    Nov 1, 2007, 00:00

  • PUK13 COST OF DIALYSIS IN A UK SETTING—A MULTICENTRE MICROCOSTING STUDY

    Nov 1, 2007, 00:00

  • PAA16 A RETROSPECTIVE STUDY COMPARING TREATMENT PATTERNS, OUTCOMES, AND RESOURCE USE BETWEEN TWO FIXED COMBINATIONS OF INHALED CORTICOSTEROIDSAND LONG-ACTING B2-AGONIST (ICS/LABA) IN ASTHMATIC PATIENTS IN GERMANY

    Nov 1, 2007, 00:00

  • PAR33 OSWESTRY HIP SCORE- A PATIENT ASSESSED TOOLTO MEASURE HIP FUNCTION

    Nov 1, 2007, 00:00

  • PAR13 ANNUAL TREATMENT COSTS OF PATIENTS WITH RHEUMATOID ARTHRITISWITH METOTREXATE AND LEFLUNOMIDE IN SPAIN

    Nov 1, 2007, 00:00

  • PRS14 THE IMPACT OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION ON QUALITY OF LIFE OF ASTHMA AND COPD PATIENTS

    Nov 1, 2007, 00:00

  • PAR24 COST-UTILITY ANALYSIS OF RITUXIMAB TREATMENT IN RHEUMATOID ARTHRITIS AFTER ANTI-TNF-ALFATHERAPY IN HUNGARY

    Nov 1, 2007, 00:00

  • PMC1 COMPARISON OF EMR DATA TO US NATIONAL DATA

    Nov 1, 2007, 00:00

  • CN1 USING THE FACT-NEUROTOXICITY TO EVALUATE QUALITY OF LIFE IN CANCER PATIENTS FROM ACROSS THE GLOBE

    Nov 1, 2007, 00:00

  • PMC26 UTILITY INDEX CALCULATION- SIMULATION STUDY CONSIDERING THE HEALTH STATUS AFTER AN INTERVENTION

    Nov 1, 2007, 00:00

  • PIN20 COST EFFECTIVENESS ANALYSIS OF BRIVUDINE COMPARED WITH ACICLOVIR FORTHETREATMENT OF HERPES ZOSTER IN SPAIN

    Nov 1, 2007, 00:00

  • PEY11 ESTIMATING NET HEALTH BENEFITS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD)

    Nov 1, 2007, 00:00

  • PST1 SEASONAL VARIATION OF TRANSIENT ISCHEMIC ATTACK (TIA) IN HUNGARY

    Nov 1, 2007, 00:00

  • PMH48 IMPACT OF COMORBIDITY ON EQ-5D-A STUDY OF HEALTH-RELATED QUALITY OF LIFE IN DEPRESSION IN A GENERAL POPULATION SURVEY

    Nov 1, 2007, 00:00

  • ND4 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN INTHE TREATMENT OF POST-HERPETIC NEURALGIA IN SCOTLAND

    Nov 1, 2007, 00:00

  • PMH45 THE IMPACT OF CHANGES IN ANTIDEPRESSANT DRUG TREATMENT IN ELDERLY NURSING HOME (NH) PATIENTS—AREAS OF POTENTIAL CARE DETERIORATION DUE TO FORMULARY POLICIES- RESULTS FROM A PILOT STUDY

    Nov 1, 2007, 00:00

  • PDB58 CHANGES IN CONCOMITANT DIABETES THERAPIES ASSOCIATED WITH THE INITIATION OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PND39 PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN PARKINSON'S DISEASE- OVERVIEW OF US AND EUROPEAN DRUG APPROVALS

    Nov 1, 2007, 00:00

  • PAA5 CLINICO-ECONOMICAL ANALYSIS OF USING BUDESONID/ FORMOTEROL INHALER FORTREATMENT OF BRONCHIAL ASTHMA

    Nov 1, 2007, 00:00

  • PCV19 A MODEL-BASED ANALYSIS OF THE EFFECTS OF INTENSIFYING LI PI D-ALTERING THERAPY ON DIRECT MEDICAL COSTS OF CORONARY HEART DISEASE EVENTS IN A SECONDARY PREVENTION POPULATION IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PDB15 LOWER RATE OF HOSPITALIZATION IN SUBSEQUENTYEAR OF INSULIN GLARGINE VS NPH INITIATION IN INDIVIDUALS WITHTYPE 2 DIABETES (T2DM)

    Nov 1, 2007, 00:00

  • PDB2 A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) PATIENTS WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD) AS ADD-ONTHERAPY

    Nov 1, 2007, 00:00

  • PCN5 THE IMPORTANCE OF A RATIONAL USE OF HIGH COSTING CHEMOTHERAPY AGENTS IN A CHEMOTHERAPY UNIT OF A TERTIARY CANCER HOSPITAL IN BRAZIL

    Nov 1, 2007, 00:00

  • PMC22 THE TURKISH WEIGHTING OF THE EUROQOL

    Nov 1, 2007, 00:00

  • PDB61 VALIDATING THE EXTERNAL VALIDITY OF RANDOMIZED CONTROLLED TRAILS WITH OBSERVATIONAL STUDIES AND CAUSAL EFFECT METHODS (PROPENSITY SCORE, MARGINAL STRUCTURE MODEL AND DOUBLY ROBUST METHODS)

    Nov 1, 2007, 00:00

  • PND4 DRUG UTILISATION AND EXPENDITURE ASSOCIATED WITH TREATMENTS OF NEUROLOGICAL DISORDERS

    Nov 1, 2007, 00:00

  • PCN40 HEXVIX FLUORESCENCE CYSTOSCOPY FOR NON-INVASIVE BLADDER CANCER MANAGEMENT- AN ECONOMIC MODEL OF THE IMPACT ON GERMAN HEALTH CARE COSTS

    Nov 1, 2007, 00:00

  • PUK17 ENDOSCOPIO INJECTION VERSUS ANTIBIOTIC PROPHYLAXIS IN THE REDUCTION OF URINARYTRACT INFECTIONS IN PATIENTS WITH VESICOURETERAL REFLUX

    Nov 1, 2007, 00:00

  • PCN23 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN ITALY

    Nov 1, 2007, 00:00

  • PMH36 A COST-UTILTY ANALYSIS OF ATOMOXETINE AGAINST CURRENT STIMULANT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY

    Nov 1, 2007, 00:00

  • PND37 A REVIEW OF PATIENT-REPORTED OUTCOMES THAT COMPLEMENT ASSESSMENTS OF SEIZURE REDUCTION IN ADULT EPILEPSY DRUG TRIALS

    Nov 1, 2007, 00:00

  • PND23 A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS TREATED WITH GLATIRAMER ACETATE INJECTION OR HIGH-DOSE INTERFERON BETA-IA

    Nov 1, 2007, 00:00

  • PCN43 COST OF INTRAVENOUS ADMINISTRATION OF BISPHOSPHONATES IN PATIENTS WITH METASTATIC BREAST CANCER

    Nov 1, 2007, 00:00

  • PRS17 SELECTION OF UTILITY INSTRUMENTS FORASTHMAAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2007, 00:00

  • PCN31 COST MINIMIZATION ANALYSIS OF CAPECITABINE+CISPLATIN IV VS 5-FLUORURACIL IV+CISPLATIN IVAS FIRST LINE THERAPY FORADVANCED GASTRIC CANCER FROM THE BRAZILIAN SOCIETAL PERSPECTIVE

    Nov 1, 2007, 00:00

  • PSM3 AN EVALUATION OF THE COST-EFFECTIVENESS OF AN EXTENDED COURSE OF VARENICLINE IN PREVENTING SMOKERS WHO HAVE QUIT FROM RELAPSING

    Nov 1, 2007, 00:00

  • PDB66 RETROSPECTIVE COMPARISON OF COMPLIANCE TO FIXED-DOSE COMBINATION VERSUS SINGLE AGENT COMBINATION THERAPY FOR THE TREATMENT OF DIABETES

    Nov 1, 2007, 00:00

  • PCN14 COST-EFFECTIVENESS OF EXEMESTANEVS, TAMOXIFEN IN POST-MENOPAUSALWOMEN WITH EARLY BREAST CANCER IN GERMANY

    Nov 1, 2007, 00:00

  • PIN34 PREDICTORS OF COSTS FOR SKIN AND SKIN STRUCTURE INFECTIONS DUE TO ST/IPH/LOCOCCUS/IUREUS USING A MANAGED-CARE PERSPECTIVE

    Nov 1, 2007, 00:00

  • PDB21 COST-EFFECTIVENESS OF STRICT “GET TO GOAL” TREATMENT DIRECTIVES IN THE TREATMENT OFYOUNGER PATIENTS WITH NEWLY DIAGNOSEDTYPE 2 DIABETES MELLITUS (T2DM)

    Nov 1, 2007, 00:00

  • PAA7 A PHARMACOECONOMIC EVALUATION OF SUBLINGUAL IMMUNOTHERAPY COMPARED TO SUBCUTANEOUS IMMUNOTHERAPY IN THE TREATMENT OF GRASS POLLEN INDUCED RHINOCONJUNCTIVITIS

    Nov 1, 2007, 00:00

  • PMH55 DEVELOPMENT AND VALIDATION OF THE SLEEP IMPACT SCALE FOR INSOMNIA

    Nov 1, 2007, 00:00

  • PMH34 A PHARMACOECONOMIC OUTCOMES ANALYSIS COMPARING RISPERIDONE LONG-ACTING INJECTION AND CONVENTIONAL DEPOT ANTIPSYCHOTICS

    Nov 1, 2007, 00:00

  • PCV36 COST-EFFECTIVENESS OF THE MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLAEMIA WITH A PREVENTIVE TREATMENT ATORVASTATIN-BASED

    Nov 1, 2007, 00:00

  • PDB63 ESTIMATING THE LONG-TERM CLINICAL OUTCOMES ASSOCIATED WITH SWITCHING TO INSULIN ASPART (NOVORAPID®) FROM HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE POLISH SETTING

    Nov 1, 2007, 00:00

  • PDB22 EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITHTYPE 2 DIABETES IN SPAIN AND ITALY

    Nov 1, 2007, 00:00

  • PG14 ECONOMIC EVALUATION COMPARING LANSOPRAZOLE AND ESOMEPRAZOLE IN THE ACUTE MANAGEMENT OF UNINVESTIGATED DYSPEPSIA

    Nov 1, 2007, 00:00

  • PDB5 GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS

    Nov 1, 2007, 00:00

  • PCN26 INNOVATION OVERTHE PRODUCT LIFE CYCLE- ESTIMATING THE POTENTIAL ECONOMIC VALUE OF TRASTUZUMAB IN BREAST CANCER IN FIVE EUROPEAN COUNTRIES BETWEEN 2000 AND 2020

    Nov 1, 2007, 00:00

  • POB4 GEMCAS MODEL—A DECISION ANALYTIC MODEL ASSESSING THE COST-EFFECTIVENESS OF TREATMENTS FOR OBESITY AND ASSOCIATED CARDIOVASCULAR RISK FACTORS

    Nov 1, 2007, 00:00

  • PIN37 COST-UTILITY OF ALFAPEGINTERFERON-2A (40 KD) IN CO-INFECTED PATIENTS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL

    Nov 1, 2007, 00:00

  • PDB59 METHODOLOGICAL APPROACH ASSESSING AN ASSOCIATION OF THE SURROGATE PARAMETER BETA-CELL ACTIVITY AND PATIENT-RELEVANT OUTCOMES IN TYPE 2 DIABETIC PATIENTS

    Nov 1, 2007, 00:00

  • PDB26 COSTS AND NEONATAL OUTCOMES AFTER INSULIN ASPART COMPARED WITH HUMAN INSULIN IN PREGNANTWOMEN WITHTYPE 1 DIABETES

    Nov 1, 2007, 00:00

  • PCN74 PSYCHOSOCIAL CONSEQUENCES OF ABNORMAL AND FALSE-POSITIVE RESULTS IN LUNG CANCER SCREENING- ADAPTATION OF A QUESTIONNAIRE

    Nov 1, 2007, 00:00

  • PSK12 PATIENT REPORTED OUTCOMES IN PSORIASIS

    Nov 1, 2007, 00:00

  • PHM17 RECOMBINANT ACTIVATED FACTOR VII (RFVIIA)VS. ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) FOR ON-DEMAND TREATMENT OF JOINT BLEEDS IN HEMOPHILIACS WITH INHIBITORS- A SYSTEMATIC REVIEW AND BAYESIAN META-REGRESSION SURVIVAL MODEL WIT ...

    Nov 1, 2007, 00:00

  • PCV79 PERSISTENCE TO ANTILIPIDEMICS VARIES BY SEX, AGE, AND RACE/ETHNICITY- ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE

    Nov 1, 2007, 00:00

  • PND22 MILD TO MODERATE ALZHEIMER'S DISEASE ASSOCIATED WITH SIGNIFICANT TIME BURDEN TO CAREGIVERS

    Nov 1, 2007, 00:00

  • PMC11 DEALING WITH COMPETING CAUSES OF DEATH, ILLNESS AND COSTS-THE DISEASE ELIMINATION LIFE TABLE ANALYSIS (DELTA) MODEL

    Nov 1, 2007, 00:00

  • PHP11 EFFICIENCY IN DRUG PRESCRIPTION MEASURED BYTHE APPLICATION OF ADJUSTED CLINICAL GROUPS IN FIVE SPANISH PRIMARY CARE CENTRES

    Nov 1, 2007, 00:00

  • PPN10 LINGUISTIC ADAPTATION INTO SPANISH AND PSYCHOMETRIC VALIDATION OF THE NEUROPATHIC PAIN SCREENING QUESTIONNAIRE- ID PAIN

    Nov 1, 2007, 00:00

  • PCN49 COST-UTILITY ANALYSIS OF MAINTENANCE THERAPY WITH RITUXIMAB FOR FOLLICULAR LYMPHOMA IN BRAZIL

    Nov 1, 2007, 00:00

  • PCV67 MANAGEMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION (STEMI) ACCORDING TO GUIDELINES IN SPAIN

    Nov 1, 2007, 00:00

  • PCV76 MEASUREMENT OF FRACTIONAL FLOW RESERVE IN PATIENTS WITH CORONARY ARTERY DISEASE TO GUIDE TREATMENT—RESULTS FROM A HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYTIC MODEL

    Nov 1, 2007, 00:00

  • PIN41 USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE ECONOMIC BURDEN OF FEBRILE NEUTROPENIA

    Nov 1, 2007, 00:00

  • PCN54 INCREASING EXPENDITURES FOR ONCOLOGY MEDICATIONS- CZECH REPUBLIC LONG-TERM DATA

    Nov 1, 2007, 00:00

  • PCV74 A COMPARATIVE PHARMACOECONOMIC ANALYSIS OF STATINS IN RUSSIA

    Nov 1, 2007, 00:00

  • PAA4 COST-EFFECTIVENESS ANALYSIS OF OMALIZUMABVS STANDARD THERAPY (ST), IN THE MANAGEMENT OF SEVERE ASHTMA

    Nov 1, 2007, 00:00

  • PCV48 MAJOR BLEED RESOURCE USE AND COSTS FOR PATIENTS HOSPITALISED WITH ACUTE CORONARY SYNDROME IN FRANCE, ITALY. AND SPAIN

    Nov 1, 2007, 00:00

  • PND2 BUDGET IMPACT ANALYSIS OF LEVETIRACETAM ADJUNCTIVE THERAPY IN PATIENTS WITH JUVENILE MYOCLONIC EPILEPSY IN SCOTLAND

    Nov 1, 2007, 00:00

  • POS7 COST-EFFECTIVENESS SIMULATION MODELING OF THE COMPLIANCE OF 5 MG ZOLEDRONIC ACID ONCE A YEAR VERSUS CURRENT TREATMENTS IN POST-MENOPAUSAL OSTEOPOROSIS

    Nov 1, 2007, 00:00

  • PSK13 PSYCHOMETRIC VALIDATION OF THE OILY SKIN SELF ASSESSMENT SCALE (OSSAS) AND THE OILY SKIN IMPACT SCALE (OSIS)

    Nov 1, 2007, 00:00

  • PSU3 THE EFFECTS OF LAPAROSCOPIC SURGERY AND NOSOCOMIAL INFECTIONS ON THE COST OF CARE- EVIDENCE FROM THREE SURGICAL PROCEDURES

    Nov 1, 2007, 00:00

  • PEY8 A EUROPEAN SURVEY OF PATIENT SATISFACTION WITH SPECTACLES AND THE ASSOCIATED COSTS IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2007, 00:00

  • PMC17 ACCOUNTING FOR INITIAL HEALTH STATUS IN MEASURING THE BENEFITS OF HEALTH CARE TECHNOLOGIES

    Nov 1, 2007, 00:00

  • Patient-Reported Outcome Instrument Selection- Designing a Measurement Strategy

    Nov 1, 2007, 00:00

  • PMH43 POTENTIAL DRUG-DRUG INTERACTIONS WITH RISPERIDONE AND THE RISK OF DISCONTINUATION- A RETROSPECTIVE ANALYSIS OF PATIENTS IN QUEBEC, CANADA

    Nov 1, 2007, 00:00

  • PCN60 IMPLEMENTATION AND EVALUATION OF CLINICAL PATHWAYS IN AN ONCOLOGY ELECTRONIC MEDICAL RECORD

    Nov 1, 2007, 00:00

  • PHM8 COST-MINIMIZATION ANALYIS OF DARBEPOETIN-α VERSUS EPOETIN-β IN DIALYSED PATIENTS- A LONG-TERM RETROSPECTIVE MONOCENTRIC ITALIAN STUDY

    Nov 1, 2007, 00:00

  • PGI27 ESTIMATION OF WEIGHTS FOR THE SPANISH VERSION OF SF-6DTO DERIVE SOCIETAL HEALTH STATE VALUES USING THE SPANISH VERSION OF SF-36VI

    Nov 1, 2007, 00:00

  • PND15 THE COST-UTILITY OF EXELON PATCH IN THE MANAGEMENT OF PATIENTS WITH MODERATE ALZHEIMER'S DISEASE IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PDB37 MEALTIME INSULIN ASPART REDUCES THE LONG-TERM COST OF COMPLICATIONS COMPARED TO HUMAN INSULIN AS PART OF BASAL-BOLUS THERAPY IN POLISH TYPE 2 DIABETES PATIENTS

    Nov 1, 2007, 00:00

  • PCV54 ATTAINMENT OF LDL CHOLESTEROL GOALS AMONG HIGH RISK PATIENTS WITH CARDIOVASCULAR DISEASE (CVD)- HOW LARGE WAS THE GAP BETWEEN EUROPE THE UNITED STATES (US) IN 2006?

    Nov 1, 2007, 00:00

  • PST3 STROKE SURVIVORS' CHANGE IN HEALTH RELATED QUALITY OF LIFE OVERTIME AS MEASURED BYTHE STROKE IMPACT SCALE

    Nov 1, 2007, 00:00

  • PSU5 SYSTEMATIC REVIEW OF PATIENT REPORTED OUTCOMES FOLLOWING INTRADISCAL ELECTROTHERMAL THERAPY (IDET) OR SPINAL FUSION FOR DISCOGENIC LOW BACK PAIN

    Nov 1, 2007, 00:00

  • PDB20 COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN AN ITALIAN SETTING. A META-ANALYSIS

    Nov 1, 2007, 00:00

  • PDB76 TREATMENT SATISFACTION IS POSITIVELY ASSOCIATED WITH GLYCEMIC CONTROLAND NEGATIVELY ASSOCIATED WITH PATIENT REPORTED EXPERIENCE OF HYPOGLYCEMIC SYMPTOMS AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AG ...

    Nov 1, 2007, 00:00

  • CASE3 REVIEWING THE REIMBURSEMENT STATUS OF DRUGS AGAINST ASTHMA, COPD AND COUGHS

    Nov 1, 2007, 00:00

  • PHM1 ASSESSING PATIENTS' RISKS OF BLOOD TRANSFUSIONS- A LITERATURE REVIEW OF PUBLISHED INCIDENCE RATES

    Nov 1, 2007, 00:00

  • PMC16 SF-6D REFERENCE VALUES FOR SPANISH GENERAL POPULATION

    Nov 1, 2007, 00:00

  • PHM11 COST UTILITY OF KNEE SURGERYWITH RECOMBINANT ACTIVATED FACTORVII (RFVIIA) IN HEMOPHILIA PATIENTS WITH INHIBITORS- AN EXPLORATORY MODEL

    Nov 1, 2007, 00:00

  • PDB48 A RETROSPECTIVE ANALYSE OF THE IMPACT OF INCREASING BODY MASS INDEX ON MEDICAL RESOURCES FOR PEOPLE WITH TYPE 2 DIABETES IN UNITED STATES

    Nov 1, 2007, 00:00

  • PND5 USE OF HEALTH CARE RESOURCES AND CORRESPONDING COSTS IN NEUROLOGICAL DISORDERS IN THE PRIMARY CARE SETTING

    Nov 1, 2007, 00:00

  • PMC29 ESTIMATING THE BUDGET IMPACT OF NEWTECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH BENEFITS IN ISRAEL- STAKEHOLDERS' INCENTIVES FOR ADOPTING A RISK-SHARING MECHANISM

    Nov 1, 2007, 00:00

  • ES1 INCREMENTAL DIFFERENCES IN RESOURCE UTILIZATION AND COSTS OFTREATING PERSONS INFECTED WITH HIV IN A LOW SOCIOECONOMIC NEIGHBORHOOD

    Nov 1, 2007, 00:00

  • ES7 ASSESSMENT OF LONG-RUN ECONOMIC BENEFITS ASSOCIATED WITH IN-VITRO FERTILIZATION (IVF) FUNDING DECISIONS-A SIMPLIFIED LIFETIME TAX CALCULATION

    Nov 1, 2007, 00:00

  • EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

    Nov 1, 2007, 00:00

  • PMC25 USING DISCRETE CHOICE EXPERIMENT MODELLING TO ASSESS PREFERENCES FOR HEALTH CARE CHARACTERISTICS

    Nov 1, 2007, 00:00

  • PMC12 DRUG ADMINISTRATION SERVICES- AN INFUSION STAGE MODEL IN A MULTI-SITE STUDY OF U.S. PHYSICIAN OFFICES

    Nov 1, 2007, 00:00

  • POS13 IMPACT OF THE ALLOWABLE GAP ON PERSISTENCE IN THE BISPHOSPHONATE MARKET

    Nov 1, 2007, 00:00

  • Patient-Reported Outcomes to Support Medical Product Labeling Claims- FDA Perspective

    Nov 1, 2007, 00:00

  • PCN30 THE ECONOMIC BENEFITS OFTEGAFURWITH URACIL (UFTORAL) IN FIRST- LINE METASTATIC COLORECTAL CANCER

    Nov 1, 2007, 00:00

  • PCV51 ESTIMATING THE IMPACT OF MANDATORY SWITCH FROM ATORVASTATINTO SIMVASTATIN IN NORWAY

    Nov 1, 2007, 00:00

  • PCV38 COST-EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION- A COMPARATIVE ANALYSIS USING CLINICAL TRIAL AND OBSERVATIONAL DATA

    Nov 1, 2007, 00:00

  • PPN2 A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV INFUSION DICLOFENAC IN POST-OPERATIVE PAIN

    Nov 1, 2007, 00:00

  • PCN24 COST-EFFECTIVENESS ANALYSIS OF 5HT3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

    Nov 1, 2007, 00:00

  • PAR32 INVESTIGATION OF RESPONSE SHIFT IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOINGTOTAL KNEE REPLACEMENT

    Nov 1, 2007, 00:00

  • CN2 DEVELOPMENT ANDVALIDATION OF OPTIMALLYWEIGHTED MEASURES OF GLOBAL HEALTH-RELATED QUALITY OF LIFE (QOL) AND UTILITY BASED ON A CANCER-SPECIFIC QOL INSTRUMENT

    Nov 1, 2007, 00:00

  • PCN46 A COST UTILITY ANALYSIS OF MAINTENANCE RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR NON HODGKINS LYMPHOMA (NHL) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PHP23 RELATIONSHIP BETWEEN RISKS FOR LIFESTYLE-RELATED DISEASES AND MEDICAL EXPENSES AFTER 10 YEARS OF METABOLIC SYNDROME

    Nov 1, 2007, 00:00

  • PGI19 INVESTIGATION OF OTC NSNSAID RATIONAL USE AND GASTROINTESTINAL DISEASES

    Nov 1, 2007, 00:00

  • PIN12 COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN COMPLICATED SKIN AND SOFT-TISSUE INFECTION DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE

    Nov 1, 2007, 00:00

  • PIN40 AN AUDIT OF HLA-B570I SCREENING METHODS AND COSTS IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PGI24 SPANISH CULTURAL ADAPTATION AND VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ)

    Nov 1, 2007, 00:00

  • PHM13 THE EFFECT OF RESTRICTING FERTILITY SERVICES IN GERMANY

    Nov 1, 2007, 00:00

  • PIN15 COST-EFFECTIVENESS OF AUGMENTIN ES® FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND

    Nov 1, 2007, 00:00

  • ND3 MODELING TREATING MULTIPLE SCLEROSISWITH DISEASE MODIFYING DRUGS USING DISCRETE EVENT SIMULATION

    Nov 1, 2007, 00:00

  • PIN28 A COST MINIMIZATION ANALYSIS COMPARING DIFFERENT ANTIBIOTIC REGIMENS USED IN TREATING PNEUMONIA IN HONG KONG

    Nov 1, 2007, 00:00

  • PIN24 THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE (6, I 1,6, 18) IN NORWAY

    Nov 1, 2007, 00:00

  • PDB57 ADMINISTRATIVE CLAIMS ANALYSIS OF NEW EXENATIDE PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • PMH15 PREVALENCE OF TREATMENT RESISTANT DEPRESSION IN USUAL CARE IN THE UNITED STATES

    Nov 1, 2007, 00:00

  • PCV73 ATOOL FOR MODELING MORTALITY DIFFERENCES IN PREDICTIVE SCREENING MODELS

    Nov 1, 2007, 00:00

  • PHP37 PHARMACOECONOMIC EDUCATION IN COLLEGES OF PHARMACY—2007

    Nov 1, 2007, 00:00

  • PMH17 COSTS OF PRESCRIPTION OPIOID ABUSE

    Nov 1, 2007, 00:00

  • PIH14 DESCRIBING YOUR HEALTH TODAY- ANALYSIS OF OPEN ANSWERS IN THE VALIDATION PROCEDURE OF THE ITALIAN EQ-5D (CHILD)VERSION

    Nov 1, 2007, 00:00

  • PSK6 IMPACT OF PSORIASIS DISEASE ON ANNUAL TOTAL HEALTH CARE COSTS AND RESOURCE UTILIZATION AMONG MEDICAID RECIPIENTS

    Nov 1, 2007, 00:00

  • PCN13 ASSESSMENT OFTHE COST-EFFECTIVENESS IN AUSTRALIA OF CETUXIMAB IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CANCERS OFTHE HEAD AND NECK

    Nov 1, 2007, 00:00

  • PND9 LEVETIRACETAM ADJUNCTIVETHERAPY FORTHE TREATMENT OF REFRACTORY PRIMARY GENERALISED TONIC-CLONIC SEIZURES- A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2007, 00:00

  • PMC19 USE OF THE RELIABLE CHANGE INDEX TO EVALUATE CLINICAL SIGNIFICANCE IN HEART TRANSPLANTS

    Nov 1, 2007, 00:00

  • ED2 LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN INTYPE 2 DIABETES PATIENTS IN THE GERMAN SETTING

    Nov 1, 2007, 00:00

  • PUK11 THE COST OF END STAGE RENAL DISEASE IN GREECE

    Nov 1, 2007, 00:00

  • PCN52 GAP BETWEEN TREATMENT COST OF AND MORTALITY DUE TO CERVICAL CANCER IN HUNGARY

    Nov 1, 2007, 00:00

  • PAA13 THE MONTREAL PROTOCOL- CONCERNS OVER THE FUTURE TREATMENT OF ASTHMA

    Nov 1, 2007, 00:00

  • PMH54 PRELIMINARY VALIDATION OF THE ENGLISH VERSION OF THE SCHIZOPHRENIA QUALITY OF LIFE (S-QOL) SCALE

    Nov 1, 2007, 00:00

  • PEY14 ASSESSMENT OF THE PERSISTENCE DEGREE IN PATIENTS WITH ANTIGLAUCOMA AGENTS AS FIRST LINE MONOTHERAPIES IN SPAIN

    Nov 1, 2007, 00:00

  • PMC28 EVALUATING THE EFFECTIVENESS OF SEARCH STRATEGIES FOR SYSTEMATIC REVIEWS

    Nov 1, 2007, 00:00

  • What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures?

    Nov 1, 2007, 00:00

  • PCV52 ATTITUDES AND BELIEFS OF PHYSICIANS ABOUT HYPERCHOLESTEROLEMIA IN SPAIN-THE PRACTICE STUDY

    Nov 1, 2007, 00:00

  • PMC34 BIBLIOGRAPHIC REVIEW OF DISCRETE EVENTS SIMULATION STUDIES IN HEALTH TECHNOLOGY EVALUATION

    Nov 1, 2007, 00:00

  • PMH21 THE COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE IN SWEDEN

    Nov 1, 2007, 00:00

  • PRS16 DEVELOPMENT OF PREFERENCE-BASED EQ-5D UTILITY VALUES FORTHE ST GEORGE'S RESPIRATORY QUESTIONNAIRE-CHRONIC OBSTRUCTIVE PULMONARY DISEASE (SGRQ-COPD)

    Nov 1, 2007, 00:00

  • EC1 RESOURCE USE AND COST OF DIAGNOSTICWORKUP OF WOMEN WITH SUSPECTED BREAST CANCER

    Nov 1, 2007, 00:00

  • PEY1 USE OF BAYESIAN NETWORKS TO SPECIFY NOCTURNAL IOP CONTROL BY PROSTAGLANDIN ANALOGUES ACCORDING TO SEVERAL THRESHOLDS FROM DAY-TIME MEASUREMENTS IN GLAUCOMA PATIENTS

    Nov 1, 2007, 00:00

  • PEY9 COST OF STANDARD CARE TREATMENT IN THE UNITED KINGDOM AMONG PATIENTS WITH PROGRESSION OF PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2007, 00:00

  • PND13 COST-EFFECTIVENESS ANALYSIS OF THE LIDOCAINE 5% MEDICATED PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN FOR POST-HERPETIC NEURALGIA IN GERMANY

    Nov 1, 2007, 00:00

  • Evaluating Health-Related Quality of Life in Cancer Clinical Trials- The National Cancer Institute of Canada Clinical Trials Group Experience

    Nov 1, 2007, 00:00

  • PUK20 A COST EFFECTIVENESS ANALYSIS OF SOLIFENACIN COMPARED WITH EXTENDED-RELEASE TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

    Nov 1, 2007, 00:00

  • PHM22 THE EMOTIONAL AND PHYSICAL BURDEN OF INJECTIONS ON PATIENTS UNDERGOING IVF

    Nov 1, 2007, 00:00

  • PAR8 LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND-A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2007, 00:00

  • PMH53 ADHERENCE AND SWITCHING WITH ANTIDEPRESSANTS

    Nov 1, 2007, 00:00

  • PMH42 THE PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS ASSOCIATED WITH ATYPICAL ANTIPSYCHOTICS WITHIN ONTARIO DRUG BENEFIT CLAIMS

    Nov 1, 2007, 00:00

  • PSK11 EVALUATION OF THE ASSOCIATION BETWEEN EQ5D UTILITY AND DERMATOLOGY LIFE QUALITY INDEX (DLQI) SCORE IN PATIENTS WITH PSORIASIS

    Nov 1, 2007, 00:00

  • PG13 BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE

    Nov 1, 2007, 00:00

  • PAA23 THE RELATIONSHIP BETWEEN QUALITY OF LIFE AND WILLINGNESS TO PAY IN PATIENTS WITH ASTHMA IN KOREA

    Nov 1, 2007, 00:00

  • PSK2 PSOBEST. EFFECTIVENESS AND SAFETY OF LONG-TERM SYSTEMIC PSORIASIS-THERAPY- PATIENT REGISTRY OF HEALTH SERVICES IN GERMANY

    Nov 1, 2007, 00:00

  • PCV85 DOES A SINGLE PILL COMBINING AMLODIPINE AND ATORVASTATIN OFFER GREATER LONG-TERM ADHERENCE BENEFIT OVER LOW-COST GENERIC 2-PILL CALCIUM CHANNEL BLOCKER/STATIN REGIMENS?

    Nov 1, 2007, 00:00

  • PAR26 THE UNINTENDED CONSEQUENCES OF WITHDRAWING DRUGS FROMTHE MARKET

    Nov 1, 2007, 00:00

  • PND10 COST EFFECTIVENESS ANALYSES OF RUFINAMIDEVS TOPIRAMATE AND LAMOTRIGINE AS ADJUNCTIVE THERAPIES IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME (LGS) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • CV8 THE COST-EFFECTIVENESS (COST-UTILITY) OF EPROSARTAN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISEASE IN BELGIUM, GERMANY, SPAIN, UNITED KINGDOM, AND SWEDEN

    Nov 1, 2007, 00:00

  • PMH4 EFFICACY OF ANTIPSYCHOTICS IN NEGATIVE SYMPTOMS OF SCHIZOPHRENIAS META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • PMC21 INFLUENCE OF “SOCIAL” AND “SCHOOL” LIFE DIMENSIONS ON CHILDREN'S QUALITY OF LIFE ASSESSED WITH EQ-5D (CHILD)

    Nov 1, 2007, 00:00

  • PIN16 COST-EFFECTIVENESS OF AUGMENTIN ES®VS AZITHROMYCIN FOR THE TREATMENT OF PAEDIATRIC ACUTE OTITIS MEDIA (AOM) IN POLAND

    Nov 1, 2007, 00:00

  • PUK8 CMA OF MYCOPHENOLAN MOFETIL (MMF; CELLCEPT) OR TACROLIMUS (TAC; PROGRAF) IN KIDNEYTRANSPLANT IMMUNOSUPPRESSIVE THERAPY SCHEMES FROM PUBLIC PAYER'S PERSPECTIVE IN POLAND

    Nov 1, 2007, 00:00

  • PIH3 ENDOMETRIOSIS-COST ESTIMATES AND METHODOLOGICAL PERSPECTIVE

    Nov 1, 2007, 00:00

  • PHM12 COST-EFFECTIVENESS OF DASATINIBVS IMATINIB 800 MG/ DAY IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN

    Nov 1, 2007, 00:00

  • PDB17 MEDICAL COSTS AMONG INDIVIDUALS WITH DIABETES, HYPERTENSION OR HYPERCHOLESTEROLEMIA

    Nov 1, 2007, 00:00

  • PPN12 TURKISH MCGILL PAIN QUESTIONNAIRE- RELIABILITY AND VALIDATION

    Nov 1, 2007, 00:00

  • PCV31 LONG-TERM COST-EFFECTIVENESS OF RIMONABANT IN GERMANY

    Nov 1, 2007, 00:00

  • ES6 COST COMPARISON BETWEEN HAEMODIALYSIS AND PERITONEAL DIALYSIS IN NORWAY FOR PATIENTSWHO CAN USE EITHER TREATMENT MODALITY

    Nov 1, 2007, 00:00

  • PUK9 HEALTH STATUS AND COSTS OF PATIENTS UNDERGOING HAEMODIALYSISTREATMENT IN HUNGARY

    Nov 1, 2007, 00:00

  • PDB77 BARRIERS TO INSULIN THERAPY QUESTIONNAIRE- HOW TO USE THE “BIT” IN DAILY PRACTICE AND SCIENCE?

    Nov 1, 2007, 00:00

  • PIH15 ADJUSTING FORTRIAL QUALITY IN A META-ANALYSIS

    Nov 1, 2007, 00:00

  • PCV4 META-ANALYSIS OF THE EFFICACY OF TELMISARTAN ON BLOOD PRESSURE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

    Nov 1, 2007, 00:00

  • PIN21 COST-EFFECTIVENESS OF INFLUENZA VACCINATION FOR HEALTHY ADULTS IN THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PCN39 THE COST OF TREATING AND MANAGING ABNORMAL CERVICAL CONDITIONS IN IRELAND

    Nov 1, 2007, 00:00

  • PMH49 SF-36 AND EQ-5D QUALITY OF LIFE INSTRUMENTS IN MAJOR DEPRESSIVE DISORDER PATIENTS- COMPARISONS OF TWO DIFFERENT TREATMENT OPTIONS

    Nov 1, 2007, 00:00

  • PMC6 THE OPERATIVE INTERVAL OF AN INCREMENTAL COST-EFFECTIVENESS RATIO-A NEW BENCHMARK FOR ASSESSING THE BOUNDARIES ON THE EFFICIENT FRONTIER CURVE

    Nov 1, 2007, 00:00

  • PDB9 INDIRECT COMPARISON OF ONCE DAILY INSULIN DETEMIR AND GLARGINE IN REDUCING WEIGHT GAIN AND ACHIEVING GLYCEMIC CONTROL, WHEN ADMINISTERED IN ADDITION TO CONVENTIONAL ORAL ANTIDIABETIC THERAPY IN THE TREATMENT OFTYPE 2 DIABETES PATIENTS; ...

    Nov 1, 2007, 00:00

  • PDB8 EVALUATION OF THE ASSOCIATION BETWEEN GLUCOSE VARIABILITY, AS MEASURED BY THE DIFFERENCE BETWEEN MAXIMUM AND MINIMUM, INTERMITTENT, RANDOM BLOOD GLUCOSE OBSERVATIONS, AND LONGTERM CLINICAL OUTCOME IN SUBJECTS WITHTYPE 2 DIABETES TREATE ...

    Nov 1, 2007, 00:00

  • PAA10 ADULT ASTHMA- A COHORT ANALYSIS OF USE AND COST OF HOSPITAL AND EMERGENCY DEPARTMENT CARE BY LOCATION OF RESIDENCE OVERTWELVE MONTHS

    Nov 1, 2007, 00:00

  • PCN75 WHAT CHOICES DO MEN FEEL THEY HAVE IN SELECTION OF PROSTATE CANCER TREATMENT?

    Nov 1, 2007, 00:00

  • PHP29 THE RELATIONSHIP BETWEEN PHYSICIAN EMPATHY AND SATISFACTION WITH PRIMARY CARE PHYSICIANS- FINDINGS FROM AN INTERNET BASED SURVEY

    Nov 1, 2007, 00:00

  • PHP5 DOES ENTRY OF GENERIC DRUGS ALWAYS RESULT IN COST-CONTAINMENT? THE HUNGARIAN EVIDENCE

    Nov 1, 2007, 00:00

  • PDB27 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN CHINA

    Nov 1, 2007, 00:00

  • PIN33 THE COST OF ZOSTERAND POST-HERPETIC NEURALGIA TREATMENT IN FRANCE

    Nov 1, 2007, 00:00

  • POS5 LITERATURE REVIEW ON THE COSTS OF NON-COMPLIANCE IN OSTEOPOROSIS

    Nov 1, 2007, 00:00

  • PRS13 CEPOC STUDY- DIAGNOSTIC VALIDITY OF INDIRECT METHOS FOR COMPLIANCE ASSESSMENT IN COPD PATIENTS

    Nov 1, 2007, 00:00

  • PMH7 TREATMENT DURATION WITH ORAL AND LONG ACTING INJECTABLE FORMULATIONS OF TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA RESULTS ACROSS WORLD GEOGRAPHIES

    Nov 1, 2007, 00:00

  • PAA22 STATE TRANSITION MODELS FOR ESTIMATING TRANSITION PROBABILITIES IN MARKOV MODELS

    Nov 1, 2007, 00:00

  • PMH30 DIRECT COSTS ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE

    Nov 1, 2007, 00:00

  • PND6 COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND NATALIZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE PRESENCE OF LONG-TERM CLINICAL EVIDENCE

    Nov 1, 2007, 00:00

  • PCV8 EPROSARTAN VERSUS OTHERANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND IN PATIENTS WITH HYPERTENSION-INDIRECT ANALYSIS

    Nov 1, 2007, 00:00

  • PMC31 EVALUATION OF THE PERSPECTIVE AND TYPE OF STUDIES IN ANIMAL HEALTH ECONOMICS

    Nov 1, 2007, 00:00

  • PCV82 FACTORS INFLUENCING COMPLIANCE WITH COMBINATION ANTIHYPERTENSIVE PHARMACOTHERAPY IN A LARGE US DATABASE

    Nov 1, 2007, 00:00

  • PCN67 ESTIMATION OF IMPORTANT DIFFERENCES IN EQ-5DVAS SCORES IN CANCER

    Nov 1, 2007, 00:00

  • Quality of Life Related to Oral versus Subcutaneous Iron Chelation- A Time Trade-off Study

    Nov 1, 2007, 00:00

  • PGI23 USING DISCRETE CHOICE EXPERIMENTS (DCE)TO MEASURE PREFERENCES FOR TREATMENT OPTIONS- AN APPLICATION TO GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

    Nov 1, 2007, 00:00

  • PIN36 COST-UTILITY OF PEGINTERFERON-ALFA-2A (40 KD) IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B WITH AND WITHOUT THE “E” ANTIGEN IN BRAZIL

    Nov 1, 2007, 00:00

  • PCV57 UTILISATION OF DRUGS FOR TREATMENT OF CARDIOVASCULAR DISEASE WITHIN SLOVAKIA

    Nov 1, 2007, 00:00

  • PCN68 SENSITIVITYTO CHANGE OF THE PERFORM QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING IMPROVEMENT OR DETERIORATION OF THEIR CANCER-RELATED FATIGUE

    Nov 1, 2007, 00:00

  • PCV3 EFFECTIVENESS OF ROSUVASTATIN COMPARED TO OTHER STATINS FORTHE PREVENTION OF FATAL AND NON-FATAL CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE— AN EPIDEMIOLOGICAL STUDY

    Nov 1, 2007, 00:00

  • PEY12 METHODOLOGICAL ISSUES ARISING FROM THREE STUDIES WHICH INCLUDED CONJOINT ANALYSIS IN VISUALLY IMPAIRED PEOPLE

    Nov 1, 2007, 00:00

  • PCV29 THE COST-EFFECTIVENESS ANALYSIS OF CORONARY ARTERY DISEASE DIAGNOSTIC PARAMETERS IN A CLINICAL LABORATORY SETTING

    Nov 1, 2007, 00:00

  • PG15 EVALUATION OF THE COST-EFFECTIVENESS OF CONCOMITANT ORAL AND TOPICAL MESALAZINE TREATMENT VERSUS ORAL TREATMENT ALONE IN MILD-TO-MODERATE ACTIVE ULCERATIVE COLITIS- A DECISION-ANALYTIC MODEL

    Nov 1, 2007, 00:00

  • PDB7 ADDITION OF INHALED HUMAN INSULIN AS AN OPTION FOR PATIENTS WITHTYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETICS SHOULD AVOID COMPLICATIONS PREDICTED BY EAGLE MODEL

    Nov 1, 2007, 00:00

  • PMC15 CONVERGENT, DISCRIMINANT, CONCURRENT VALIDITY AND RELIABILITY OF THE EQ-5D(CHILD)- RESULTS

    Nov 1, 2007, 00:00

  • PHP24 TRENDS OF PATIENT COSTS PER CASE IN ALBERTA, CANADA

    Nov 1, 2007, 00:00

  • PDB42 COSTS ASSOCIATED WITH THE FIRST SIX MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM- DATA FROM THE INSTIGATE STUDY

    Nov 1, 2007, 00:00

  • PMH1 PRESCRIBING PATTERNS, PREDICTORS, AND COSTS ASSOCIATED WITH ANTIDEPRESSANT TREATMENTS FOR PERSONS WITH MAJOR DEPRSSIVE DISORDER (MDD) AND COMORBID PAIN

    Nov 1, 2007, 00:00

  • CN4 COST-EFFECTIVENESS OF PEGYLATED LIPISOMAL DOXORUBICIN VS. CONVENTIONAL DOXORUBICIN IN AVOIDANCE OF CARDIOTOXICITY FOR METASTATIC BREAST CANCER IN THE FIRST TREATMENTYEAR

    Nov 1, 2007, 00:00

  • PND30 ANALYSIS OF TRIPTAN REFILLING BEHAVIOR AMONG FEMALE MIGRAINEURS

    Nov 1, 2007, 00:00

  • PND27 ESTIMATING MARGINAL COST-EFFECTIVENESS USING A PERSON-LEVEL NET BENEFITS APPROACH WITH AN APPLICATION TO DISEASE-MODIFYING DRUGS IN MULTIPLE SCLEROSIS

    Nov 1, 2007, 00:00

  • PIN46 A CROSS-SECTIONAL VALIDATION OF THE MINI-HIV QUESTIONNAIRE

    Nov 1, 2007, 00:00

  • PMC7 THE USE OF DISEASE TRANSMISSION MODELLING IN COST-EFFECTIVENESS ANALYSES- STRENGTHS AND WEAKNESSES

    Nov 1, 2007, 00:00

  • PMH24 THE COST EFFECTIVENESS OF PALIPERIDONE EXTENDED-RELEASE OROS IN SWEDEN, FINLAND, DENMARK AND NORWAY

    Nov 1, 2007, 00:00

  • PCV42 ANTICOAGULATION CONTROL IN DIFFERENT SETTINGS OF CARE- PERCEPTION, DIRECT NON-HEALTH CARE COSTS AND PRODUCTIVITY LOSSES AMONGST PATIENTS WITH ATRIAL FIBRILLATION IN AN ITALIAN REGION

    Nov 1, 2007, 00:00

  • POS14 COMPARISON OF SF-6DAND EQ-5D UTILITIES IN OSTEOPOROTIC HIP FRACTURE PATIENTS

    Nov 1, 2007, 00:00

  • PHP3 BUDGET SILO MENTALITY BEHIND THE FORMER IRON CURTAIN-A CASE STUDY FROM HUNGARY

    Nov 1, 2007, 00:00

  • SU2 MICRO-COSTING OF SURGICAL PROCEDURES RELATED TO INTRACEREBRAL HAEMORRHAGE IN A UK HEALTH CARE SETTING

    Nov 1, 2007, 00:00

  • PHM5 ADVATE IS COST-EFFECTIVE INVESTMENT IN HEMOPHILIA A TREATMENT WHEN PATHOGENS EMERGE—A SCENARIO-BASED ECONOMIC AND POSITIVE INVESTMENT INTERVAL (Pll) EVALUATION

    Nov 1, 2007, 00:00

  • PRS18 A PROCESS FOR DEVELOPING A PATIENT-CENTERED CONCEPTUAL FRAMEWORK FOR DYSPNEA AND RELATED FUNCTIONAL LIMITATIONS IN COPD

    Nov 1, 2007, 00:00

  • PIH1 ASSOCIATION BETWEEN CENTRAL PRECOCIOUS PUBERTY AND COMORBID MEDICAL ILLNESS- LARGE-SCALE RETROSPECTIVE CLAIMS ANALYSIS OF FLORIDA MEDICAID-ENROLLED CHILDREN

    Nov 1, 2007, 00:00

  • PND17 TREATMENT COSTS ASSOCIATED WITH RESTLESS LEGS SYNDROME IN ITALY

    Nov 1, 2007, 00:00

  • HP1 HEALTH SYSTEM CORRELATES OF RECEIPT OF RADIATION AFTER BREAST CONSERVING SURGERY IN LOW-INCOME MEDICAID-ENROLLEDWOMEN

    Nov 1, 2007, 00:00

  • PCN7 PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH FILGRASTIM IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING CHOP-21 IN SPAIN

    Nov 1, 2007, 00:00

  • PMH18 PRESCRIBING PATTERN OF CITALOPRAM AND ESCITALOPRAM IN THE CANTON OF GENEVA A POTENTIAL FOR MAJOR SAVINGS

    Nov 1, 2007, 00:00

  • PHP15 PREFERENCES FOR DRUG REIMBURSEMENT CRITERIA IN SOUTH KOREA USING DISCRETE CHOICE EXPERIMENTS

    Nov 1, 2007, 00:00

  • PCN47 COST-UTILITY ANALYSIS OF OXALIPLATIN IN THE ADJUVANT TREATMENT OF COLON CANCER IN HUNGARY

    Nov 1, 2007, 00:00

  • PG111 IMPACT OF CONSTIPATION ON HEALTH CARE UTILIZATION AND COSTS IN PATIENTS ON OPIOID THERAPY

    Nov 1, 2007, 00:00

  • PIH7 COST-EFFECTIVENESS OF MAGNETIC RESONANCE IMAGE-GUIDED FOCUSED ULTRASOUND (MRGFUS) FOR THE TREATMENT OF UTERINE FIBROIDS

    Nov 1, 2007, 00:00

  • PHP25 MEDICATION ADHERENCE IN POST-TRANSPLANT IMMUNOSUPPRESSION-THE ECONOMIC IMPACT OF DRUG-REGIMEN COMPLEXITY

    Nov 1, 2007, 00:00

  • PAR27 WITHDRAWAL OF ROFECOXIB FROMTHE MARKET; THERAPEUTIC AND ECONOMIC IMPLICATION FOR THE NETHERLANDS

    Nov 1, 2007, 00:00

  • PCV62 PRIVATE PAYER EPISODE COSTS OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHYVS. MYOCARDIAL PERFUSION IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE

    Nov 1, 2007, 00:00

  • Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis- The ESPRINT Questionnaire

    Nov 1, 2007, 00:00

  • PCV70 MULTINOMIAL PROPENSITY SCORE ESTIMATORS AND MULTIVARIATE EXPLANATORYTECHNIQUES IN A REAL-LIFE ACUTE CORONARY HEART DISEASE STUDY—THE QALYS AND COSTS OF MEDICATION, PTCAAND CABG TREATMENT MODALITY ARE HIGHLY DEPENDENT ON THE METHODS US ...

    Nov 1, 2007, 00:00

  • PMH20 RESOURCE USE AND COSTS ASSOCIATED WITH CHANGES IN ANTIDEPRESSANT TREATMENT IN A MANAGED CARE POPULATION WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2007, 00:00

  • PAR29 AZATHIOPURINE, TPMT POLYMORPHISMS AND ADRS- THE COST OF NEUTROPENIA

    Nov 1, 2007, 00:00

  • MC3 THE DEVELOPMENT OF AN INCREMENTAL WILLINGNESS TO PAY CURVE DERIVED FROM A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PRS6 ECONOMIC BURDEN OF DISEASE OF PULMONARY ARTERIAL HYPERTENSION IN GERMANY- AN INTERIM ANALYSIS OF RESOURCE UTILISATION

    Nov 1, 2007, 00:00

  • Development, Validation, and Application of a Microsimulation Model to Predict Stroke and Mortality in Medically Managed Asymptomatic Patients with Significant Carotid Artery Stenosis

    Nov 1, 2007, 00:00

  • PDB23 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN A POLISH SETTING

    Nov 1, 2007, 00:00

  • POS3 THE ROLE OF SURGICAL DELAY ON EARLY MORTALITY IN PATIENTS WITH FEMORAL NECK FRACTURE

    Nov 1, 2007, 00:00

  • PMC20 UTILITYWEIGHTED COMPAREDTO UNWEIGHTED EQ-5D AND HUI3 SUMMARY SCORES- IMPLICATIONS FOR STATISTICAL INFERENCE

    Nov 1, 2007, 00:00

  • PAR22 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH ABATACEPT (ORENCIA) FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCV6 ESTIMATING THE INCREMENTAL BENEFIT ON FINAL OUTCOMES OF ROSUVASTATIN 40 MG OVER 20 MG IN THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLAEMIA BASED ON A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2007, 00:00

  • PCV90 INTEGRATION OF PATIENT-RATED OUTCOMES INTO CLINICAL ROUTINE IN INPATIENT AND OUTPATIENT CARDIAC REHABILITATION PROGRAMMES

    Nov 1, 2007, 00:00

  • PGI16 AN EXPLORATORY ANALYSIS OF HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH PEDIATRIC CROHN'S DISEASE

    Nov 1, 2007, 00:00

  • PSK7 EVALUATION OF THE ASSOCIATION BETWEEN PSORIASIS SEVERITY AND HOSPITAL RESOURCE USE IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • ES8 COST-EFFECTIVENESS OF DARUNAVIR/R IN HIGHLY TREATMENT-EXPERIENCED HIV/AIDS PATIENTS IN DIFFERENT EUROPEAN HEALTH CARE SETTINGS

    Nov 1, 2007, 00:00

  • PRS11 MARKOV MODEL FOR COPD- COMPARING TREEAGE AND ARENA SOFTWARE AND VALIDATING THE MODEL

    Nov 1, 2007, 00:00

  • PCV12 USING ADMINISTRATIVE DATA FOR QUALITY INDICATORS OF AMI HOSPITAL CARE IN HUNGARY

    Nov 1, 2007, 00:00

  • ES2/PMH44 COSTS AND OUTCOMES OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF ACUTE SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • POS12 USE OF OSTEOPOROSIS MEDICATIONS FOLLOWING A FRACTURE

    Nov 1, 2007, 00:00

  • PRS7 ANALYSIS OF THE PREDICTIVE ABILITY OF DIAGNOSTIC COST GROUPS, RXGROUPS, AND PRIOR COST FORTEXAS MEDICAID COPD PATIENTS

    Nov 1, 2007, 00:00

  • PCV40 STUDY OF THE COST OF OUTPATIENT HYPERTENSION THERAPY IN BULGARIA

    Nov 1, 2007, 00:00

  • PCN48 SUNITINIB MALATE PROVIDES ADDITIONAL SURVIVAL AND VALUE FOR MONEY AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC)—AN ECONOMIC EVALUATION USING BAYESIAN APPROACH

    Nov 1, 2007, 00:00

  • PCN73 LINGUISTIC VALIDATION OF THE HOT FLASH DIARY FOR PROSTATE CANCER PATIENTS IN EIGHT LANGUAGES FOR NINE COUNTRIES

    Nov 1, 2007, 00:00

  • PAR17 A SYSTEMATIC REVIEW OFTHE GLOBAL COST-OF-ILLNESS OF RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PIN13 COST-EFFECTIVENESS OF LINEZOLID VS. VANCOMYCIN IN NOSOCOMIAL PNEUMONIA DUE TO SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN FRANCE

    Nov 1, 2007, 00:00

  • PRS2 A COST-MINIMIZATION ANALYSIS COMPARING MOXIFLOXACIN VERSUS LEVOFLOXACIN AND CEFTRIAXONE FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA- RESULTS FROM THE MOTIVTRIAL

    Nov 1, 2007, 00:00

  • PAA8 COST OF REFRACTORY SEVERE PERSISTENT ASTHMA IN CZECH REPUBLIC—COST OF ILLNESS STUDY

    Nov 1, 2007, 00:00

  • Value in Health

    Nov 1, 2007, 00:00

  • PMC32 U.S. PHYSICIANS- A METHOD TO REPORT QUALITY MEASURES FOR CMS PAY-FOR-PERFORMANCE BONUS COMPENSATION

    Nov 1, 2007, 00:00

  • MD1 IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

    Nov 1, 2007, 00:00

  • PIH12 HORMONE REPLACEMENT THERAPY OF MENOPAUSAL WOMEN—ANALYSIS OF PRESCRIPTION PATTERN CHANGES BEFORE AND AFTER THE WHI STUDY USING CLAIMS DATA OF A GERMAN SICKNESS FUND

    Nov 1, 2007, 00:00

  • PMC10 SPATIAL INTERPOLATION

    Nov 1, 2007, 00:00

  • PAR2 DOES RACE INFLUENCE A PATIENT'S LIKELIHOOD OF BEING PRESCRIBED SELECTIVE CYCLOOXYGENASE-2 INHIBITORS (COX-2S) VERSUS OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS) IN MEDICAID MANAGED CARE PLANS (MCOS)?

    Nov 1, 2007, 00:00

  • PUK7 A COST-MINIMIZATION ANALYSIS OF OXYBUTYNIN (TRANSDERMAL DELIVERY SYSTEM) COMPARED TO TOLTERODINE (TABLETS) IN THE TREATMENT OF PATIENTS WITH URGE OR MIXED URINARY INCONTINENCE IN SWEDEN

    Nov 1, 2007, 00:00

  • PRS4 RELATIONSHIP BETWEEN TIME OF DURATION OF COPD AND FREQUENCY OF DISEASE EXACERBATIONS

    Nov 1, 2007, 00:00

  • PCN61 MULTI-STATE SURVIVAL ANALYSIS IN COST-EFFECTIVENESS STUDIES-THE CASE OF CAPECITABINE VERSUS DOCETAXEL IN METASTATIC BREAST CANCER (MBC) FORA PRIVATE PAYER IN BRAZIL

    Nov 1, 2007, 00:00

  • PMH12 24-MONTH TREATMENT DISCONTINUATION RATES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION (RLAI) VERSUS ORAL ANTIPSYCHOTICS- RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) ...

    Nov 1, 2007, 00:00

  • PAR4 ASSOCIATION BETWEEN SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) AND HEALTH CARE COSTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PIN7 BURDEN OF PAEDIATRIC ROTAVIRUS GASTROENTERITIS AND POTENTIAL BENEFITS OF A UNIVERSAL VACCINATION PROGRAMME IN GERMANY

    Nov 1, 2007, 00:00

  • PHP31 EUROPEAN PRICING AND REIMBURSEMENT UPDATE- OPTIMAL MONETARY BENEFITS CAN DEPEND ON WHICH COUNTRYTHE PROCESS IS INITIATED

    Nov 1, 2007, 00:00

  • PIN23 COST-EFFECTIVENESS ANALYSIS OF THE IMPLEMENTATION OF A QUADRIVALENT (6,1 1, 16,18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING BELGIAN CERVICAL CANCER SCREENING PROGRAMME

    Nov 1, 2007, 00:00

  • PHP7 INTERNATIONAL COMPARISON OF GENERIC MEDICINE PRICES

    Nov 1, 2007, 00:00

  • PCV63 ESTIMATING A SOUTH AFRICAN PHARMACOECONOMIC THRESHOLD FOR PHARMACEUTICAL DECISION MAKING

    Nov 1, 2007, 00:00

  • PDB4 A PHARMACOECONOMIC EVALUATION FOR DIABETES TYPE 2 (DM 2) WITH INHIBITORS OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) ANDTHIAZOLIDINEDIONES (TZD) IN MONOTHERAPY

    Nov 1, 2007, 00:00

  • PG17 COST-EFFECTIVENESS ANALYSIS OF TREATING CHORNIC HEPATITITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN EARLY BEFORE DISEASE PROGRESSES TO MORE ADVANCED STAGE

    Nov 1, 2007, 00:00

  • PND31 DEVELOPMENT OF THE ALZHEIMER'S DISEASE CAREGIVER PREFERENCE QUESTIONNAIRE

    Nov 1, 2007, 00:00

  • PND19 ECONOMIC EVALUATION OF INTERFERON-Â-IB IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME (CIS)

    Nov 1, 2007, 00:00

  • PCV55 LIPID LOWERING AGENTS CONSUMPTION AND COSTS IN THE SLOVAK REPUBLIC

    Nov 1, 2007, 00:00

  • PDB69 DETERMINANTS OF STOPPING TREATMENT WITH ORAL ANTIDIABETIC DRUGS IN DAILY CLINICAL PRACTICE

    Nov 1, 2007, 00:00

  • MC2 BAYESIAN MODELING OF RESOURCE USE ALONGSIDE MULTINATIONAL RANDOMISED CLINICAL TRIALS

    Nov 1, 2007, 00:00

  • PIN1 SYSTEMATIC REVIEW OF THE SAFETY OF ANTIRETROVIRAL THERAPIES FOR REDUCING THE RISK OF MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION

    Nov 1, 2007, 00:00

  • SU4 THE COST-EFFECTIVENESS OFTITANIUM CAGE VERSUS FEMORAL RING ALLOGRAFT IN CIRCUMFERENTIAL LUMBAR FUSION-A RANDOMISED CONTROLLED TRIAL

    Nov 1, 2007, 00:00

  • PUK18 INCREASING MARKET SHARE OF PRIVATE DIALYSIS CENTRES FROM HEALTH INSURANCE EXPENDITURES IN HUNGARY

    Nov 1, 2007, 00:00

  • PND38 LONGITUDINAL PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA- A POST-HOC ANALYSIS OF A 12-WEEK PROSPECTIVE STUDY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE

    Nov 1, 2007, 00:00

  • PDB54 FACTORS ASSOCIATED WITH CONTINUED CLINICAL INERTIA AMONG PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2007, 00:00

  • ES3 COST-EFFECTIVENESS OF FIRST EYE CATARACT SURGERY IN ELDERLY WOMEN- A RANDOMISED CONTROLLED TRIAL

    Nov 1, 2007, 00:00

  • PEY3 RANIBIZUMAB (LUCENTIS®) IS A COST-EFFECTIVE TREATMENT OF AGE-RELATED MACULA DEGENERATION (AMD) IN THE GERMAN HEALTH CARE SYSTEM

    Nov 1, 2007, 00:00

  • PCV45 COST-UTILITY ANALYSIS OF RIMONABANT IN THE MANAGEMENT OF OBESITY/OVERWEIGHT PATIENTS WITH CARDIOMETABOLIC RISK FACTORS IN HUNGARY

    Nov 1, 2007, 00:00

  • PHP9 INFLUENCE OF POLYPHARMACY BY APPLYING THE ADJUSTED CLINICAL GROUPS CLASSIFICATION IN A SPANISH POPULATION SETTING-A CROSS-SECTIONAL STUDY

    Nov 1, 2007, 00:00

  • PMH23 COST-EFFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US

    Nov 1, 2007, 00:00

  • PIN32 OUTCOMES AND COSTS OF HOSPITAL-ACQUIRED PNEUMONIA ASSOCIATED WITH PSEUDOMONAS OR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN A SAMPLE OF BELGIAN HOSPITALS

    Nov 1, 2007, 00:00

  • PCV32 COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION, TYPE-2 DIABETES AND RENAL DAMAGE IN MEXICO

    Nov 1, 2007, 00:00

  • PMC9 PREVALENCE OF CONDITIONS IN THE US EMPLOYER INSURED POPULATIONS METHODOLOGY FOR PROJECTING FROM A CONVENIENCE SAMPLE

    Nov 1, 2007, 00:00

  • PPN8 CHRONIC PAIN TREATMENT WITH OPIOIDS- PRACTICE DOES NOT FOLLOW POLICY

    Nov 1, 2007, 00:00

  • PR3 PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS

    Nov 1, 2007, 00:00

  • PAR11 COST-EFFECTIVENESS OF ADDING LEFLUNOMIDE TO STANDARD DRUG SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN POLAND

    Nov 1, 2007, 00:00

  • PCV91 HEALTH OUTCOMES IN PATIENTS WITH HYPERTENSION- WHAT HAVE WE IMPROVED IN TEN YEARS?

    Nov 1, 2007, 00:00

  • PND26 USE OF A COUNSELLING GUIDELINE FOR THE DETECTION OF DRUG RELATED PROBLEMS IN PARKINSON'S DISEASE

    Nov 1, 2007, 00:00

  • Productivity Costs Associated with Cardiometabolic Risk Factor Clusters in the United States

    Nov 1, 2007, 00:00

  • PCN21 A HEALTH ECONOMIC EVALUATION OF HEXVIXAS ADJUNCT TO STANDARD WHITE LIGHT CYSTOSCOPY IN THE MANAGEMENT OF SUPERFICIAL BLADDER CANCER

    Nov 1, 2007, 00:00

  • PR5 VALIDATION OF POMS QUESTIONNAIRE IN POSTMENOPAUSALWOMEN

    Nov 1, 2007, 00:00

  • Performance Comparison of Likert and Binary Formats of SF-36 Version 1.6 Across ECRHS II Adults Populations

    Nov 1, 2007, 00:00

  • PAR12 FINANCIAL CONSEQUENCES OFTHERAPEUTIC STRATEGIES IN OSTEOARTHRITIS TREATMENT IN CZECH REPUBLIC

    Nov 1, 2007, 00:00

  • PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA

    Nov 1, 2007, 00:00

  • PND8 COST-EFFECTIVENESS ANALYSIS OF AMBULATORY CARE STRATEGY FOR PATIENTS WITH TRANSIENT ISCHEMIC ACCIDENT (TIA) VERSUS THE STANDARD PROTOCOL BASED ON HOSPITALISATION

    Nov 1, 2007, 00:00

  • PCV10 MULTIPLE REGRESSION ANALYSIS MODEL PREDICTED DIASTOLIC BLOOD PRESSURE

    Nov 1, 2007, 00:00

  • PND3 BUDGET IMPACT OF DOPAMINE AGONISTS IN POLAND

    Nov 1, 2007, 00:00

  • PUK3 REIMBURSEMENT INCENTIVE FOR PERITONEAL DIALYSIS MAY GENERATE BUDGET SAVINGS FOR ROMANIA

    Nov 1, 2007, 00:00

  • PHM14 PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) CHALLENGE TRANSFUSION RESOURCES NOW AND IN THE FUTURE

    Nov 1, 2007, 00:00

  • PCV58 COMPARISON OF REASONS BEHIND PHYSICIANS' ANTIHYPERTENSIVE THERAPY CHOICE IN THE UNITED STATES (US) AND EUROPE

    Nov 1, 2007, 00:00

  • PDB79 THE DIABETES MEDICATION SATISFACTION TOOL (DMSAT)- DEVELOPMENT AND VALIDATION OF A NEW PATIENT-CENTERED OUTCOMES INSTRUMENT FOR CLINICIANS

    Nov 1, 2007, 00:00

  • PMH25 COST EFFETIVENESS OF AMISULPRID IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • Interpreting and Reporting Results Based on Patient-Reported Outcomes

    Nov 1, 2007, 00:00

  • PCV68 CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS)

    Nov 1, 2007, 00:00

  • PCV65 LIKELIHOOD OF INITIATING ANTILIPIDEMICS BY PATIENT SEX, RACE/ETHNICITY, AGE, AND COMORBIDITY- LARGE-SCALE ANALYSIS OF FLORIDA MEDICAID-ENROLLED ADULTS WITH NEWLY DIAGNOSED DYSLIPIDEMIA

    Nov 1, 2007, 00:00

  • POS6 COST-EFFECTIVENESS OF OSTEOPOROSIS SCREENING CAMPAIGN FOR BELGIAN WOMEN

    Nov 1, 2007, 00:00

  • PCV16 HEALTH INSURANCE COSTS OF STROKE HOSPITAL TREATMENTS IN HUNGARY; 2003-2005

    Nov 1, 2007, 00:00

  • PRS1 ACUTE EFFECTS OF SILDENAFIL ON ECHOCARDIOGRAGHIC PARAMETERS IN PATIENTS WITH PRIMARY PULMONARY HYPERTENSION

    Nov 1, 2007, 00:00

  • PND18 HEALTH AND NON-HEALTH RESOURCES UTILIZATION AND DERIVED COSTS OF TREATING UNDER ROUTINE MEDICAL PRACTICE REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA IN PRIMARY CARE SETTING (PCS)- A 12-WEEKS LONGITUDINAL POST-HOC ANALYSIS

    Nov 1, 2007, 00:00

  • International Price Comparisons for Novel and Follow-on Drugs

    Nov 1, 2007, 00:00

  • ND1 COST-EFFECTIVENESS OF INTRATHECAL BACLOFEN THERAPY VERSUS CURRENT THERAPIES IN DISABLED SPASTICITY

    Nov 1, 2007, 00:00

  • PUK14 TIME SPENT ON ANAEMIA MANAGEMENT WITH ERYTHROPOIETIN STIMULATING AGENTS (ESA) IN HAEMODIALYSIS CENTRES- A CROSS-COUNTRIES PERSPECTIVE

    Nov 1, 2007, 00:00

  • PND7 AN ANALYTICAL MODEL TO PREDICT THE COST-EFFECTIVENESS OF LONG-TERM ESZOPICLONE FOR THE TREATMENT OF PRIMARY INSOMNIA

    Nov 1, 2007, 00:00

  • PDB31 TOTAL COST REDUCTION IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS TREATED WITH PIOGLITAZONE (PIO) BASED THERAPIES VERSUS NON-THIAZOLIDINEDIONE (NON-TZD) BASED THERAPIES

    Nov 1, 2007, 00:00

  • PMH52 USAGE AND PERSISTENCY OF ATYPICAL ANTI-PSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2007, 00:00

  • PDB51 DRUG USE FOR DIABETES MELLITUSTYPE 2 AND ITS COMPLICATIONS IN SLOVAKIA

    Nov 1, 2007, 00:00

  • PIH18 VALIDITY OF A CHILD-FRIENDLY EQ-5D AS A GENERIC HEALTH OUTCOME INSTRUMENT IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS IN GERMANY

    Nov 1, 2007, 00:00

  • PMC30 ECONOMIC ADVANTAGES OF ONLINE DISCRETE EVENT SIMULATION TRAINING

    Nov 1, 2007, 00:00

  • PUK21 THE IMPACT OF ICODEXTRIN ON QUALITY OF LIFE IN DIABETIC PATIENTS ON PERITONEAL DIALYSIS OVERTIME- A REGRESSION ANALYSIS

    Nov 1, 2007, 00:00

  • PIH10 AN ECONOMIC ASSESSMENT OF THE CONTENT OF HOME PHARMACIES AND SELF MEDICATION PRACTICE AMONG FAMILIES IN SLOVAK REPUBLIC AND SERBIA CITIES

    Nov 1, 2007, 00:00

  • ED3 DIFFERENCES IN HEALTH RELATED RESOURCE USE IN THE 6 MONTHS PRIOR TO AND AFTER INSULIN INITIATION IN PATIENTS WITHTYPE 2 DIABETES IN GERMANY AND UNITED KINGDOM- DATA FROMTHE INSTIGATE STUDY

    Nov 1, 2007, 00:00

  • Methods for Integrating Medication Compliance and Persistence in Pharmacoeconomic Evaluations

    Nov 1, 2007, 00:00

  • PAA19 BI-MODALITY IN DISTRIBUTION OF MEDICATION POSSESSION RATIOS FOR ASTHMA CONTROLLER THERAPIES

    Nov 1, 2007, 00:00

  • PCV20 EVALUATING GENDER DIFFERENCES IN HEALTH CARE RESOURCE USE AND OUTCOMES AMONG ELDERLY PATIENTS WITH CONGESTIVE HEART FAILURE

    Nov 1, 2007, 00:00

  • CASE4 DEVELOPMENT ANDVALIDATION OF A CAREGIVER GASTROENTERORITIS KNOWLEDGE QUESTIONAIRE

    Nov 1, 2007, 00:00

  • PHM23 PATIENTS', PHYSICIANS'AND PHARMACISTS' PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES TO TREAT PATIENTS WITH INHIBITORS- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PHM18 BEST-WORST CASE SCALING IN DISCRETE CHOICE EXPERIMENTS- AN APPLICATION IN A RARE DISEASE POPULATION

    Nov 1, 2007, 00:00

  • PAR6 A COST EFFECTIVENESS PRELIMINARY STUDY ON A NEW TOTAL KNEE ARTHROPLASTY SYSTEM AND A PERIPHERAL NERVE BLOCKADETECHNIQUE

    Nov 1, 2007, 00:00

  • PCV50 COSTS OF MAJOR BLEEDS IN ACUTE CORONARY SYNDROME PATIENTS

    Nov 1, 2007, 00:00

  • RS3 IMPACT OF SOCIO-ECONOMIC FACTORS ON PATIENTS' KNOWLEDGE OFTHEIR CONDITION, INVOLVEMENT IN TREATMENT DECISIONS ANDTHE SUBSEQUENT COMPLIANCE WITHTHEIR TREATMENT REGIMEN

    Nov 1, 2007, 00:00

  • PHP17 RECOMMENDATIONS FROM REIMBURSEMENT AGENCIES FORADDITIONAL POST-LAUNCH RESEARCH. THE NEXT HURDLE

    Nov 1, 2007, 00:00

  • PCV23 HOSPITAL COSTS FORTREATMENT OF ACUTE HEART FAILURE- ECONOMIC ANALYSIS OF THE REVIVE II STUDY

    Nov 1, 2007, 00:00

  • PAR28 GEOGRAPHICAL VARIATION OF PHARMACOLOGICAL PRESCRIPTION WITH BAYESIAN HIERARCHICAL MODELS

    Nov 1, 2007, 00:00

  • PMS1 DIRECT HEALTH COSTS OF TREATING PATIENTS WITH FIBROMYALGIA IN PRIMARY CARE SETTINGS (PCS) UNDER ROUTINE MEDICAL PRACTICE-A COST OF ILLNESS STUDY USING A CLAIM DATABASE IN SPAIN

    Nov 1, 2007, 00:00

  • PCV34 COST-EFFECTIVENESS OF ATORVASTATIN PLUS AMLODIPINE VERSUS ATORVASTATIN PLUS ATENOLOL IN HYPERTENSIVE PATIENTS WITHOUT PREVIOUS CORONARY HEART DISEASE, NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS AND AT LEAST 3 CARDIOVASCULAR RISK FAC ...

    Nov 1, 2007, 00:00

  • PDB38 COST OF ILLNESS STUDY OFTYPE-2 DIABETES IN COLOMBIA

    Nov 1, 2007, 00:00

  • PND28 COMPARISON OF FOUR PREFERENCE-BASED SF-36/SF-I2 ALGORITHMS TO EVALUATE THE COST-EFFECTIVENESS OF TREATMENT FOR PRIMARY INSOMNIA WITH ESZOPICLONE

    Nov 1, 2007, 00:00

  • PGI29 UPPER Gl SYMPTOMS IN GREEK PATIENTS RECEIVING ASPIRIN/NSAIDS

    Nov 1, 2007, 00:00

  • PMH51 ADHERENCE OF ALZHEIMER PATIENTS TO ANTIDEMENTIA DRUGS

    Nov 1, 2007, 00:00

  • PCN15 ESTIMATING THE COST EFFECTIVENESS OF PROPHYLACTIC CERVICAL CANCERVACCINATION IN IRELAND USING A MATHEMATICAL MODEL

    Nov 1, 2007, 00:00

  • PR7 PATIENT'S PREFERENCES FOR OSTEOPOROSIS DRUG TREATMENT- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2007, 00:00

  • PG113 THE EPIDEMIOLOGY AND HEALTH CARE RESOURCE USE IN PATIENTS WITH CROHN'S DISEASE- A POPULATION BASED UK STUDY

    Nov 1, 2007, 00:00

  • PCN25 PHARMACOECONOMIC EVALUATION OF CAPECITABINE (XELODA) FOR GASTRIC CANCER IN THE UNITED KINGDOM

    Nov 1, 2007, 00:00

  • PCN77 PHARMACOECONOMIC ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NON-SMALL-CELL LUNG CANCER (NSCLC) IN TURKEY

    Nov 1, 2007, 00:00

  • PCV46 ECONOMIC EVALUATION OF 80 MG ATORVASTATIN COMPARED TO 20-40 MG SIMVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES

    Nov 1, 2007, 00:00

  • PHM15 POSITIVE INVESTMENT INTERVAL (PII)AND PAYBACK PERIOD (PP) OFFER DIFFERENT INTERPRETATIONS IN HEALTH TECHNOLOGY INVESTMENT DECISIONS- Pll ISA MATTER OF BEING AND PP IS A MATTER OF TURNING BENEFICIAL—A CASE OF HEMOPHILIA A

    Nov 1, 2007, 00:00

  • PUK5 RETROSPECTIVE PHARMACOECONOMIC STUDY OF THE USE OF CYCLOSPORINE A MICROEMULSION (SANDIMMUN® NEORAL®) IN COMPARISON WITH CYCLOSPORINE A GENERICS FOR IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION

    Nov 1, 2007, 00:00

  • PHP16 ASSESSMENT OF DECISION MAKER NEEDS RELATED TO HEALTH ECONOMIC MODELS AND DATA ANALYSIS TOOLS

    Nov 1, 2007, 00:00

  • PIN45 HOWTO IMPROVE THE EXTERNAL VALIDITY AND EXTEND THE EXPIRATION DATE OF ECONOMIC EVALUATIONS

    Nov 1, 2007, 00:00

  • PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS

    Nov 1, 2007, 00:00

  • PPN1 INCIDENCE OF ACUTE PAIN IN TURKEY

    Nov 1, 2007, 00:00

  • PEY1O- OXIDATIVE STRESS IN ADVANCED PRIMARY OPEN-ANGLE GLAUCOMA

    Nov 1, 2007, 00:00

  • PGI25 DEVELOPMENT AND VALIDATION OF PATIENT REPORTED OUTCOMES MEASUREMENT SCALES FOR CROHN'S DISEASE- THE INFLAMMATORY BOWEL DISEASE IMPACT AND SYMPTOM SCALES (IBDIMSYS)

    Nov 1, 2007, 00:00

  • PIN26 THE COST-EFFECTIVENESS OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN HUNGARY

    Nov 1, 2007, 00:00

  • PAR30 SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2007, 00:00

  • PUK15 AN INTERNATIONAL ECONOMIC EVALUATION OF SEVELAMER HYDROCHLORIDE VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS NEW TO DIALYSIS

    Nov 1, 2007, 00:00

  • PUK22 AN OBSERVATIONAL STUDY ON THE HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH A NEUROGENIC OVERACTIVE BLADDER TREATED WITH TOLTERODINE ER

    Nov 1, 2007, 00:00

  • PCN58 BREAST CANCER SCREENING PROGRAMS- EVALUATION ASIDE FROM CLINICAL AND ECONOMICAL ASPECTS

    Nov 1, 2007, 00:00

  • PMC8 THE USE OF ADMNISTRATIVE DATABASE IN ITALY- INSIGHTS FROM THE FRIULIVENEZIA GIULIA CASE

    Nov 1, 2007, 00:00

  • PHP27 A NEW REGRESSION MODEL AND QUALITY PERFORMANCE ADJUSTMENT IN PHYSICIAN ECONOMIC PROFILING

    Nov 1, 2007, 00:00

  • PCN42 COST ANALYSIS OF SEPSIS MANAGEMENT AFTER MYELOSUPPRESSIV CHEMOTHERAPY IN NSCLC AND LYMPHPOMA PATIENTS- A GERMAN HOSPITAL PERSPECTIVE

    Nov 1, 2007, 00:00

  • PCV9 DIFFERENT REDUCTIONS OF HOSPITALISATIONS FOR CARDIOVASCULAR EVENTS AMONG 92035 USERS OF STATINS IN A REAL LIFE SETTING

    Nov 1, 2007, 00:00

  • PIH5 COSTS AND OUTCOMES ASSOCIATED WITH USE OF RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH) DURING IN VITRO FERTILISATION (IVF) TREATMENT IN A UNITED KINGDOM CENTRE

    Nov 1, 2007, 00:00

  • PR6 PATIENT CHARACTERISTICS IMPACTING QUALITY OF LIFE (EQ-5D) OF FEMALES WITH STRESS URINARY INCONTINENCE SYMPTOMS

    Nov 1, 2007, 00:00

  • PIH9 ESTIMATION OF HEALTH CARE PROFESSIONALS'TIME INPUT USING MULTI-DIMENSIONAL WORK SAMPLING (MDWS)

    Nov 1, 2007, 00:00

  • HP3 ASSESSING THE IMPACT OF A NATIONAL DRUG BENEFIT PROGRAM ONTHE USE OF GENERIC DRUGS AND DIFFERENT THERAPEUTIC CLASSES

    Nov 1, 2007, 00:00

  • DB3 CLINICAL AND PATIENT REPORTED OUTCOMES OVER THE FIRST 6 MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY ANDTHE UNITED KINGDOM- DATA FROMTHE INSTIGATE STUDY

    Nov 1, 2007, 00:00

  • PSU4 RETROSPECTIVE STUDY OF COMPLICATIONS AND RESOURCE USE IN ENDOVASCULAR MANAGEMENT OF AAA

    Nov 1, 2007, 00:00

  • Patient-Reported Outcomes- Conceptual Issues

    Nov 1, 2007, 00:00

  • PMH33 AN EVALUATION OF HEALTH CARE COSTS WITH A DISEASE MANAGEMENT PROGRAM FOR ADULTS WITH SCHIZOPHRENIA IN A MEDICAID POPULATION USING PROPENSITY SCORE MATCHING

    Nov 1, 2007, 00:00

  • PCN17 COST-EFFECTIVENESS ANALYSIS OFTRASTUZUMAB THERAPY IN PATIENTS WITH EARLY HER-2 POSITIVE BREAST CANCER IN BRAZIL

    Nov 1, 2007, 00:00

  • PCN51 COMPARING THE BURDEN OF CANCER AND OTHER DISEASES WITH THE ECONOMIC RESOURCES ALLOCATED TO THOSE DISEASES- A SOUTH AFRICAN PERSPECTIVE

    Nov 1, 2007, 00:00

  • PCN45 UK COST-EFFECTIVENESS ANALYSES OF DOCETAXEL VERSUS GENERIC PACLITAXEL ONCE WEEKLY AND NAB-PACLITAXEL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) PROGRESSED AFTERANTHRACYCLINE CHEMOTHERAPY

    Nov 1, 2007, 00:00

  • PAR14 COST MINIMIZATION ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB AND ETANERCEPT FOR RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2007, 00:00

  • PND34 A QUALITATIVE STUDY OF THE INDIVIDUALISED IMPACT OF RESTLESS LEGS SYNDROME (RLS) ON QUALITY OF LIFE

    Nov 1, 2007, 00:00

  • PMH27 COST-EFFECTIVENESS OF DULOXETINE VS. VENLAFAXINE XRAND SSRIS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN PRIMARY AND SECONDARY CARE IN SPAIN

    Nov 1, 2007, 00:00

  • PIN10 COST-EFFECTIVENESS OF DIFFERENT PERTUSSIS VACCINATION STRATEGIES FORTHE PROTECTION OF YOUNG INFANTS

    Nov 1, 2007, 00:00

  • PHP2 A DETERMINATION OF TOPICS FOR HEALTH TECHNOLOGY ASSESSMENT IN THAILAND

    Nov 1, 2007, 00:00

  • PCV18 ECONOMIC BENEFIT OF IMPROVED PRESERVATION OF EXPLANTED ORGANS IN HEART TRANSPLANTATION

    Nov 1, 2007, 00:00

  • SU3 NINEYEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING IN CONTEXT OF SURVIVAL AND COMPLICATIONS

    Nov 1, 2007, 00:00

  • PIH21 CORRELATES OF PATIENT SATISFACTION WITH PHYSICIAN VISIT- DIFFERENCES BETWEEN ELDERLY AND NON-ELDERLY SURVEY RESPONDENTS

    Nov 1, 2007, 00:00

  • PCV5 EPROSARTAN VERSUS OTHERANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND (IRBESARTAN, LOSARTAN, TELMISARTAN AND VALSARTAN) IN PATIENTS WITH HYPERTENSION-DIRECT ANALYSIS

    Nov 1, 2007, 00:00

  • Analysis and Interpretation of Results Based on Patient-Reported Outcomes

    Nov 1, 2007, 00:00

  • PCN2 RETROSPECTIVE CHART REVIEW OFTHE MANAGEMENT OF HAND-FOOT SYNDROME IN THE TREATMENT OF COLORECTAL CANCER

    Nov 1, 2007, 00:00

  • PCN63 META-ANALYTIC, TRIAL-LEVEL APPROACH TO VALIDATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT IN ADVANCED BREAST CANCER

    Nov 1, 2007, 00:00

  • PCN44 ADJUVANTTRASTUZUMAB TREATMENT IN EARLY STAGE BREAST CANCER- COST-EFFECTIVENESS IN THE BELGIAN HEALTH CARE SETTING

    Nov 1, 2007, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160 (current)
  • »